ArticleBMC cancer2022

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).

K van den Berg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.